Cell and Gene Therapy Meeting on the Mesa

Accelerate CGT Therapy Trials with Syneos Health

Cell and gene therapy (CGT) represents a new frontier in the fight against rare genetic disorders and cancers.

Complex study designs, challenging patient populations and distinct operational delivery requirements are the norm in CGT clinical trials. New treatment approaches are often unfamiliar to investigators, site staff and patients alike.

Built on nearly two decades of experience in the field, the Syneos Health Cell and Gene Therapy Consortium is the hub for our knowledge and experience, demonstrated by: 130+ cell and gene therapy trials in the past five years, and 50+ commercials projects, 350+ clinical staff with cell and gene experience, 60+ cell and gene-focused functional leaders and a specialized cell and gene therapy communications group, Genicos. Our dedicated experts know the cell and gene therapy terrain intimately and use that in-depth knowledge to help inform CGT study designs, strategic decision-making, and operational study planning. We understand that behind every decision, delay or mistake, a patient’s life is at stake.

Meet with us at the Cell and Gene Therapy Meeting on the Mesa to discuss how our collective knowledge and insights can be fully leveraged to deliver solutions specific to the needs of your trial—and make each study as safe and effective for patients as possible.